Projects per year
Fingerprint
Dive into the research topics where Andrew Parsonson is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
PROCEADE PanTumor: CTU: PROCEADE PanTumor Master Protocol: A Phase 1b/2, Multicenter, Open-Label Study of the Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants with Advanced Solid Tumors [substudy - gastric, NSCLC, pancreatic]
Parsonson, A. (Primary Chief Investigator), Armstrong, E. (Clinical Trial Unit Staff), Chapman, N. (Clinical Trial Unit Staff), Quinlan, G. (Clinical Trial Unit Staff), TAIDI, G. (Clinical Trial Unit Staff), Martin, L. (Clinical Trial Unit Staff) & Garcia, M. (Clinical Trial Unit Staff)
2/05/25 → 26/02/26
Project: Research
-
CTU: A Phase 2, Open-Label, Randomized, Master Protocol Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations with Telisotuzumab Adizutecan in Subjects with Metastatic Colorectal Cancer (AndroMETa-CRC-533)
Parsonson, A. (Primary Chief Investigator), McHugh, T. (Clinical Trial Unit Staff), Martin, L. (Clinical Trial Unit Staff), Garcia, M. (Clinical Trial Unit Staff), Quinlan, G. (Clinical Trial Unit Staff), TAIDI, G. (Clinical Trial Unit Staff), Armstrong, E. (Clinical Trial Unit Staff) & Chapman, N. (Clinical Trial Unit Staff)
24/04/25 → 23/04/30
Project: Research
-
CTU: A Phase I Study to Evaluate the Safety, Pharmacokinetics and Anti-tumor Activity of SSGJ-709 in Patients with Advanced Malignant Tumors
Parsonson, A. (Primary Chief Investigator), Quinlan, G. (Clinical Trial Unit Staff), Armstrong, E. (Clinical Trial Unit Staff), Chapman, N. (Clinical Trial Unit Staff), Martin, L. (Clinical Trial Unit Staff), Garcia, M. (Clinical Trial Unit Staff) & Chik, J. (Clinical Trial Unit Staff)
23/04/25 → 23/04/26
Project: Research
-
CTU: A First-in-Human, Open-Label, Multi-Center Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ALK201 for Injection in Adult Participants with Advanced Solid Tumors
Parsonson, A. (Primary Chief Investigator), Quinlan, G. (Clinical Trial Unit Staff), Armstrong, E. (Clinical Trial Unit Staff), Chapman, N. (Clinical Trial Unit Staff), Garcia, M. (Clinical Trial Unit Staff) & Martin, L. (Clinical Trial Unit Staff)
18/12/24 → 24/09/26
Project: Research
-
CTU: A phase 1, multicenter, open-label, first-in-human, dose escalation and expansion study of DM005 in patients with advanced solid tumors
Parsonson, A. (Primary Chief Investigator), Chapman, N. (Clinical Trial Unit Staff), Quinlan, G. (Clinical Trial Unit Staff), Martin, L. (Clinical Trial Unit Staff), TAIDI, G. (Clinical Trial Unit Staff), Garcia, M. (Clinical Trial Unit Staff) & Armstrong, E. (Clinical Trial Unit Staff)
9/12/24 → 9/09/26
Project: Research
-
A phase II trial of DB-1311/BNT324 (B7H3 ADC) combined with BNT327 (PD-L1 x VEGF-A bsAb) or DB-1305/BNT325 (TROP2 ADC) in advanced/metastatic solid tumors
Guo, Y., Gourdin, T. S., Chaudhry, A., Parsonson, A., Lin, C.-C., Jiang, L., Mu, H., Yang, Y., Fang, H., Qiu, Y., Shi, R., Tibes, R., Wenger, M., Furlanetto, J., Tureci, O., Sahin, U., Ren, Z. & Guo, J., Sept 2025, In: Annals of Oncology. 36, Supplement 2, p. S621 1 p., 1017eTiP.Research output: Contribution to journal › Meeting abstract › peer-review
Open Access -
DB-1311/BNT324 (a novel B7H3 ADC) in patients with heavily pretreated castrate-resistant prostate cancer (CRPC).
Parsonson, A. O., Gandhi, C., Henick, B. S., Schmidt, A. L., Ye, D., Amin, H., Wise-Draper, T. M., Courtney, K. D., Tam, L., Jiang, S., Gourdin, T. S., Lisberg, A., Tibes, R., Furlanetto, J., Fang, L., Qiu, Y., Shi, R., Wei, J., Zhang, B. & Stein, M. N., Jun 2025, In: Journal of Clinical Oncology. 43, 16 Supplement, 1 p., 5015.Research output: Contribution to journal › Meeting abstract › peer-review
Open Access -
PANNA-COTA (Practical assessment of NECTA network assistance in cancer outpatient trials access): a prospective investigator-led trial using ctDNA to inform early phase trial matching
Liu, J. J., Farrow, M., Hsing, S., Cosman, R., Lemech, C., Teng, C., Pal, A., Nindra, U., Parsonson, A., Park, J. J. W., Underhill, C. R., Hui, M. N., Nagrial, A., Jain, S. S. & Joshua, A. M., Sept 2025, In: Annals of Oncology. 36, Supplement 2, p. S609 1 p., 991P.Research output: Contribution to journal › Meeting abstract › peer-review
Open Access -
Patient satisfaction with Telehealth as an element of hybrid decentralised clinical trials: a cross-sectional study of oncology clinical trial participants
Parsonson, A., Karikios, D., Park, J., Sabanathan, D., Gurney, H., Zhang, A., Gilchrist, J., Chan, W. Y., Kim, S., Harrison, W., Narayanan, S., Boyle, F. & Lau, A., Aug 2025, In: Asia-Pacific Journal of Clinical Oncology. 21, Supplement 3, p. 27-28 2 p.Research output: Contribution to journal › Meeting abstract › peer-review
-
Patient satisfaction with telehealth as an element of hybrid decentralized clinical trials (DCTs): a cross-sectional study of oncology clinical trial participants
Parsonson, A. O., Karikios, D. J., Park, J. J., Sabanathan, D., Gurney, H., Zhang, A. Y., Gilchrist, J., Chan, W. Y., Kim, S., Harrison, W., Narayanan, S., Boyle, F. M. & Lau, A. Y. S., 1 Jun 2025, In: Journal of Clinical Oncology. 43, 16 Supplement, p. E13884 1 p.Research output: Contribution to journal › Meeting abstract › peer-review
Open Access